Major Depressive Disorder Clinical Trials

95 studies are recruiting for major depressive disorder in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

   Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over on…

   Stage

   Phase 2

   Ages

   8 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Locations

   2 in total

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT00018057 on ClinicalTrials.gov

2. Defining Neurobiological Links Between Substance Use and Mental Illness

   Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting comp…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   National Institute on Drug Abuse, Baltimore, Maryland

   Run by

   National Institute on Drug Abuse (NIDA)

   See if you can join NCT05538910 on ClinicalTrials.gov

3. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

   This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   University of Alabama at Birmingham, Huntsville, Alabama

   Locations

   69 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT05850689 on ClinicalTrials.gov

4. Natural History of Depression, Bipolar Disorder and Suicide Risk

   Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT06462196 on ClinicalTrials.gov

5. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Huntsville, Alabama

   Locations

   120 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

6. Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

   The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).

   Stage

   Not phased

   Ages

   22 to 85

   Site

   Emory Healthcare, Atlanta, Georgia

   Locations

   4 in total

   Run by

   Motif Neurotech, Inc.

   See if you can join NCT07594483 on ClinicalTrials.gov

7. Dupilumab in Major Depressive Disorder

   This study aims primarily to test target engagement of dupilumab by assessing changes in peripheral immune markers following interleukin-4 receptor alpha (IL-4Rα) blockade in adults with major depressive disorder (MDD). Secondary aims include evaluating safety, tolerability, feasibility, and open-l…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   The Dennis S. Charney, MD, Depression and Anxiety Discovery Center, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07908563 on ClinicalTrials.gov

8. Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

   Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works. Objective: To see if the antidepressant …

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT03973268 on ClinicalTrials.gov

9. Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

   Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objectiv…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT03065335 on ClinicalTrials.gov

10. Tracking Response to Antidepressants in Advance of Investigational Trials

    TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational tria…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Adams Clinical, Watertown, Massachusetts

    Run by

    Adams Clinical

    See if you can join NCT04748276 on ClinicalTrials.gov

11. Study of ALTO-300 in MDD

    The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Site 200, Phoenix, Arizona

    Locations

    75 in total

    Run by

    Alto Neuroscience

    See if you can join NCT05922878 on ClinicalTrials.gov

12. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

    Stage

    Phase 3

    Ages

    18 to 74

    Site

    Preferred Research Partners, Inc., Little Rock, Arkansas

    Locations

    30 in total

    Run by

    Definium Therapeutics US, Inc.

    See if you can join NCT07592689 on ClinicalTrials.gov

13. A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The primary objective of this study is to evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Neurocrine Clinical Site, Oceanside, California

    Locations

    61 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07196501 on ClinicalTrials.gov

14. A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

    The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, sel…

    Stage

    Phase 2

    Ages

    21 to 65

    Site

    The Ohio State University Department of Psychiatry, Columbus, Ohio

    Run by

    Ohio State University

    See if you can join NCT06820723 on ClinicalTrials.gov

15. In-patient SCC TMS

    The investigators are studying the feasibility, safety, and tolerability of administering accelerated repetitive Transcranial magnetic stimulation(a-rTMS) at frequencies other than standard 10 Hz for in-patient Subjects diagnosed with Major Depressive Disorder. Participants will be recruited from t…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    UCLA TMS Service and Research Service, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT05645575 on ClinicalTrials.gov

16. Cortical rTMS as a Treatment for Depression

    Depression is a leading cause of disability worldwide with a 19% lifetime prevalence in the United States. Dysfunctional reward processing is one of the core features of depression. Common treatments of depression include psychological therapies (e.g., cognitive behavioral therapy), medication (e.g…

    Stage

    Not phased

    Ages

    18 to 64

    Site

    The Menninger Clinic, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT05487911 on ClinicalTrials.gov

17. Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

    The goal of this clinical trial is to learn how different types of non-invasive brain stimulation affect mood and brain function in adults with major depressive disorder (MDD). It will also study how brain stimulation may work together with antidepressant treatments. The main questions this study a…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Bellefield Towers, Pittsburgh, Pennsylvania

    Run by

    Marta Peciña, MD PhD

    See if you can join NCT06976840 on ClinicalTrials.gov

18. Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

    Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating ea…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05523817 on ClinicalTrials.gov

19. JAK Signaling in Depression

    This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor…

    Stage

    Phase 2

    Ages

    25 to 55

    Site

    Emory University, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT07003997 on ClinicalTrials.gov

20. DBS for TRD With the Medtronic Percept PC

    Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depression (TRD), which…

    Stage

    Not phased

    Ages

    25 to 70

    Site

    Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York, New York

    Run by

    Helen Mayberg, MD

    See if you can join NCT05773755 on ClinicalTrials.gov

21. Accelerated TMS for Perinatal Depression

    We are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, traditional TMS invo…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06968390 on ClinicalTrials.gov

22. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Neurocrine Clinical Site, Bryant, Arkansas

    Locations

    19 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07105111 on ClinicalTrials.gov

23. Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

    The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation …

    Stage

    Phase 1

    Ages

    21 to 45

    Site

    Wells Medicine, Houston, Texas

    Locations

    2 in total

    Run by

    Texas A&M University

    See if you can join NCT06480201 on ClinicalTrials.gov

24. Near Infrared Spectroscopy (NIRS) for Assessment of Depression

    Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control,…

    Stage

    Not phased

    Ages

    18 and older

    Site

    San Francisco Veterans Affairs Medical Center, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT04061148 on ClinicalTrials.gov

25. Decoding and Modulating Affective Brain States

    The research study is being conducted to study brain patterns of negative emotion and develop personalized brain stimulation protocols to disrupt these patterns with transcranial magnetic stimulation (TMS). First, the investigators will use functional Magnetic Resonance Imaging (fMRI) data to gener…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT05437705 on ClinicalTrials.gov